A phase I study of mirvetuximab soravtansine (IMGN853) and gemcitabine (G) in patients with FOLR1-positive recurrent epithelial ovarian (EOC), endometrial cancer (EC), or triple-negative breast cancer (TNBC).

Mihaela C. Cristea,Paul Frankel,Timothy W. Synold,Joanne E. Mortimer,Daphne Stewart,Edward Wenge Wang,Alexander Jung,Sharon P. Wilczynski,Gottfried E. Konecny,Dia Parungao,Melissa Eng,Lindsay Kilpatrick,Yi-Jen Chen,Scott Glaser,Ernest S. Han,Thanh H. Dellinger,Amy Hakim,Stephen J. Lee,Robert J. Morgan,Mark T. Wakabayashi

A phase I study of mirvetuximab soravtansine (IMGN853) and gemcitabine (G) in patients with FOLR1-positive recurrent epithelial ovarian (EOC), endometrial cancer (EC), or triple-negative breast cancer (TNBC).

2019

3009Background: IMGN853 is an antibody-drug conjugate targeting the folate receptor alpha (FOLR1), linked to maytansinoid, DM4. IMGN853 has promising single agent activity in FOLR1+ EOC. The recomm...

Keywords:

MIRVETUXIMAB SORAVTANSINE
Oncology
Pathology
Gemcitabine
Endometrial cancer
Triple-negative breast cancer
Medicine
Internal medicine
Conjugate
in patient
Folate Receptor Alpha
Maytansinoid
Cancer research
phase i study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations